Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

British Journal of Haematology

Volumn 141, Issue 5, 2008, Pages 745-747

  De Lavallade, Hugues ^a   Punnialingam, Sinthiya ^a   Milojkovic, Dragana ^a   Bua, Marco ^a   Khorashad, Jamshid S ^a   Gabriel, Ian H ^a   Chaidos, Aristeidis ^a   Olavarria, Eduardo ^a   Goldman, John M ^a   Apperley, Jane F ^a   Marin, David ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmunity; Chronic myeloid leukaemia; Dasatinib; Pleural effusions; Toxicity

Indexed keywords

DASATINIB;

ADULT; AGED; AUTOIMMUNE DISEASE; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DRUG WITHDRAWAL; HUMAN; INCIDENCE; LETTER; LUNG TOXICITY; MAJOR CLINICAL STUDY; PANNICULITIS; PATHOGENESIS; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; RASH; RISK FACTOR; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PYRIMIDINES; RETROSPECTIVE STUDIES; THIAZOLES;

EID: 43449091001     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07108.x     Document Type: Letter

References (8)

1. Bergeron, A., Bergot, E., Vilela, G., Ades, L., Devergie, A., Esperou, H., Socie, G., Calvo, F., Gluckman, E., Ribaud, P., Rousselot, P. Tazi, A. (2002) Hypersensitivity pneumonitis related to imatinib mesylate. Journal of Clinical Oncology, 20, 4271 4272.
2. Bergeron, A., Rea, D., Levy, V., Picard, C., Meignin, V., Tamburini, J., Bruzzoni-Giovanelli, H., Calvo, F., Tazi, A. Rousselot, P. (2007) Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. American Journal of Respiratory and Critical Care Medicine, 176, 814 818.
3. Cortes, J., Rousselot, P., Kim, D.W., Ritchie, E., Hamerschlak, N., Coutre, S., Hochhaus, A., Guilhot, F., Saglio, G., Apperley, J., Ottmann, O., Shah, N., Erben, P., Branford, S., Agarwal, P., Gollerkeri, A. Baccarani, M. (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109, 3207 3213.
4. Guilhot, F., Apperley, J., Kim, D.W., Bullorsky, E.O., Baccarani, M., Roboz, G.J., Amadori, S., de Souza, C.A., Lipton, J.H., Hochhaus, A., Heim, D., Larson, R.A., Branford, S., Muller, M.C., Agarwal, P., Gollerkeri, A. Talpaz, M. (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 109, 4143 4150.
5. Hochhaus, A., Kantarjian, H.M., Baccarani, M., Lipton, J.H., Apperley, J.F., Druker, B.J., Facon, T., Goldberg, S.L., Cervantes, F., Niederwieser, D., Silver, R.T., Stone, R.M., Hughes, T.P., Muller, M.C., Ezzeddine, R., Countouriotis, A.M. Shah, N.P. (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 109, 2303 2309.
6. Jayson, G.C., Parker, G.J., Mullamitha, S., Valle, J.W., Saunders, M., Broughton, L., Lawrance, J., Carrington, B., Roberts, C., Issa, B., Buckley, D.L., Cheung, S., Davies, K., Watson, Y., Zinkewich-Peotti, K., Rolfe, L. Jackson, A. (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. Journal of Clinical Oncology, 23, 973 981.
7. Quintas-Cardama, A., Kantarjian, H., O'Brien, S., Borthakur, G., Bruzzi, J., Munden, R. Cortes, J. (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. Journal of Clinical Oncology, 25, 3908 3914.
8. Rix, U., Hantschel, O., Durnberger, G., Remsing Rix, L.L., Planyavsky, M., Fernbach, N.V., Kaupe, I., Bennett, K.L., Valent, P., Colinge, J., Kocher, T. Superti-Furga, G. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood, 110, 4055 4063.